Charles River Laboratories International (CRL) Liabilities from Discontinued Operations (2009 - 2018)
Charles River Laboratories International (CRL) posted Liabilities from Discontinued Operations of $3.5 million for Q1 2018, down 11.82% on a QoQ basis from $3.9 million in Q4 2017, and down 34.42% year-over-year from $5.3 million in Q1 2017.
Analysis
Charles River Laboratories International (CRL) Liabilities from Discontinued Operations (2009 - 2018) Analysis & Trends
Charles River Laboratories International has reported Liabilities from Discontinued Operations for 10 years, with the latest figure at $3.5 million in Q1 2018.
- On a quarterly basis, Liabilities from Discontinued Operations fell 34.42% year-over-year to $3.5 million in Q1 2018; TTM through Mar 2018 was $3.5 million, a 34.42% decrease from a year earlier, with the FY2017 full-year figure at $3.9 million, down 31.69% from the prior year.
- Liabilities from Discontinued Operations was $3.5 million for Q1 2018 at Charles River Laboratories International, down from $3.9 million in the prior quarter.
- The five-year high for Liabilities from Discontinued Operations was $8.4 million in Q4 2014, with the low at $3.5 million in Q1 2018.
- Average Liabilities from Discontinued Operations over 5 years is $6.5 million, with a median of $7.1 million recorded in 2015.
- The sharpest annual moves came in 2015 and 2018: Liabilities from Discontinued Operations advanced 4.23% in 2015, then sank 34.42% in 2018.
- Over 5 years, Liabilities from Discontinued Operations stood at $8.4 million in 2014, then retreated by 5.59% to $7.9 million in 2015, then retreated by 26.86% to $5.8 million in 2016, then plunged by 31.69% to $3.9 million in 2017, then decreased by 11.82% to $3.5 million in 2018.
- The last three Liabilities from Discontinued Operations figures came in at $3.5 million (Q1 2018), $3.9 million (Q4 2017), and $4.4 million (Q3 2017), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2018 | 3.48 Mn |
| Dec 30, 2017 | 3.94 Mn |
| Sep 30, 2017 | 4.40 Mn |
| Jul 1, 2017 | 4.85 Mn |
| Apr 1, 2017 | 5.30 Mn |
| Dec 31, 2016 | 5.77 Mn |
| Sep 24, 2016 | 6.21 Mn |
| Jun 25, 2016 | 7.09 Mn |
| Mar 26, 2016 | 7.42 Mn |
| Dec 26, 2015 | 7.89 Mn |
| Sep 26, 2015 | 7.14 Mn |
| Jun 27, 2015 | 7.55 Mn |
| Mar 28, 2015 | 7.94 Mn |
| Dec 27, 2014 | 8.36 Mn |
| Sep 27, 2014 | 7.88 Mn |
| Jun 28, 2014 | 8.27 Mn |
| Mar 29, 2014 | 7.62 Mn |
| Dec 28, 2013 | 8.08 Mn |
| Sep 28, 2013 | 10.48 Mn |
| Jun 29, 2013 | 11.26 Mn |